Skip to content

PT-141 (Bremelanotide): Clinical Evidence and Product Differences

PT-141 is bremelanotide, a melanocortin receptor agonist. Clinical evidence and the Vyleesi approval concern a defined formulation and population—not a general sexual-performance claim or every product sold under the molecule's name.

By Peptide Mag Editorial. Updated . Source and review policy.

Identity
Bremelanotide; also called PT-141
Mechanism class
Melanocortin receptor agonist
Key clinical context
Premenopausal women with acquired, generalized HSDD

The Simple Truth

Why this exists and what it’s supposed to do.

PT-141 exists because desire and blood flow are different problems.

Drugs like sildenafil work on blood vessels, and do nothing for someone whose difficulty is wanting sex in the first place.

What it is supposed to do: increase sexual desire by acting on melanocortin pathways in the brain, in both men and women — arousal rather than plumbing.

This is one of the few compounds here with an approved product and real trials behind it, for a specific condition in women. Nausea and flushing are common.

What PT-141 refers to

PT-141 is a development name for bremelanotide. The Vyleesi prescribing information identifies a melanocortin receptor agonist supplied as a finished injection. A molecular alias, a research-material label and an approved medicine are different kinds of information.

This distinction matters when reading older intranasal research or comparing it with later subcutaneous studies. Route, formulation, exposure and the question being tested need to stay attached to the result. A reference to bremelanotide alone does not establish that two preparations were interchangeable.

What the RECONNECT trials measured

The 2019 primary publication reports two randomized, double-blind, placebo-controlled phase 3 studies lasting 24 weeks. They randomized 1,267 premenopausal women with hypoactive sexual desire disorder; the efficacy analysis included 1,202 participants. Desire and distress related to low desire were the coprimary outcomes.

Bremelanotide improved those scores compared with placebo. Nausea, flushing and headache occurred more often with active treatment. The enrolled population and symptom measures are important: this was not a demonstration of universal sexual enhancement, an erectile-dysfunction trial in men or a comparison of retail research vials.

Read the size and relevance of the score changes alongside statistical significance. A favorable average difference does not mean every participant benefited, and a symptom questionnaire answers a different question from a physiological measurement or a count of encounters. The paper supplies the endpoint definitions and analysis context.

What longer follow-up adds—and misses

A 52-week open-label extension followed eligible core-study completers. Of 684 people who entered, 272 completed the extension. The authors reported sustained symptom improvements and no new safety signal during that follow-up.

The extension was not a fresh randomized placebo comparison. Enrollment selected people who completed the earlier phase, and substantial attrition limits interpretation. Its observations should not be presented as a guarantee of long-term safety for every person, a different route or an uncharacterized preparation.

The approval has a specific scope

The US label specifies acquired, generalized HSDD in premenopausal women under defined diagnostic conditions. It explicitly excludes use as a sexual-performance enhancer and does not indicate treatment of HSDD in men or postmenopausal women. An approved indication belongs to that finished product, not automatically to an independently supplied powder.

The label also addresses cardiovascular contraindications, transient blood-pressure increases, hyperpigmentation, nausea and interactions. Those are substantive clinical considerations, not footnotes to a benefits list. The approved-product document is the appropriate place to inspect the complete conditions of use; this guide is not an individual prescribing assessment.

How to compare a new PT-141 claim

Check whether the claim concerns the same population, formulation, route and endpoint as its citation. A study of desire-related distress cannot silently establish a different outcome. A trial registration is useful for checking the design, but it is not a substitute for reported results.

For a product comparison, molecular identity and purity are only the beginning. Finished-product quality, delivery characteristics and the clinical setting matter too. The clinical papers explain bremelanotide research; they do not validate a personal reconstitution recipe, dose escalation plan or treatment cycle for research material.

Sources and further reading

  1. Bremelanotide RECONNECT phase 3 trials — PMID 31599840
  2. RECONNECT open-label extension — PMID 31599847
  3. Vyleesi US prescribing information

Continue reading